WallStSmart
UTHR

United Therapeutics Corporation

NASDAQ: UTHR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$571.07
+0.34% today

Updated 2026-04-29

Market cap
$25.03B
P/E ratio
20.48
P/S ratio
7.86x
EPS (TTM)
$27.89
Dividend yield
—
52W range
$272 – $608
Volume
0.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

United Therapeutics Corporation (UTHR) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$571.07
Consensus
$561.57
-1.66%
2030 Target
$1,637.95
+186.82%
DCF
$521.18
+8.70% MoS
14 analysts:
10 Buy4 Hold0 Sell

Management guidance

CEO Martine Rothblatt has not provided explicit multi-year revenue guidance in available materials. However, recent Q4 2025 earnings showed $3.18B TTM revenue with 10.61% YoY growth, and management guided FY2026 revenue to $3.41B (7.05% growth). The company's strong pipeline success (TETON-1 IPF approval pathway, ralinepag PAH indication expansion) and $2B share buyback authorization suggest confidence in sustained growth trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$2,767.57
$6.0B Rev × 20x P/S
Base case (2030)
$1,637.95
$6.0B Rev × 12x P/S
Bear case (2030)
$1,129.62
$6.0B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2029 (E)2030 (E)
Revenue$2.3B$2.9B$3.2B$3.4B$3.9B$5.2B$6.0B
Revenue growth—23.6%10.6%7.3%13.2%16.5%17.5%
EPS$19.84$24.60$27.90$29.87$33.42$45.20$53.10
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$960.18$1,073.14$1,412.03$1,637.95

Catalysts & risks

Growth catalysts
+ TETON-1 IPF FDA supplemental NDA approval (expected 2026-2027, $5-10B market opportunity per Jefferies)
+ Ralinepag PAH label expansion with 55% clinical worsening reduction showing exceptional efficacy
+ Tyvaso franchise expansion into IPF as potential first-in-class inhaled anti-fibrotic treatment
+ Organ manufacturing/xenotransplantation program advancement (long-term differentiation)
+ $2B share repurchase program ($1.5B accelerated) supporting EPS accretion
Key risks
- IPF market competition from other inhaled antifibrotics in development; regulatory approval delays
- PAH market saturation and pricing pressure from generic/biosimilar competition
- Clinical trial execution risk for Phase 2/3 programs in organ manufacturing and novel indications
- Insider selling by CEO and executives (combined >$176M in Q4/Q1 2026) may signal valuation concerns
- Reliance on core Tyvaso/Remodulin franchise; diversification risk if pipeline misses

Methodology

United Therapeutics Corporation's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.